Brief: Aldeyra Therapeutics Enters Into Exclusive Option Agreement With AbbVie For License To Develop And Commercialize Reproxalap

Aldeyra Therapeutics

01/11/2023 11:12

Nov 1 (Reuters) - Aldeyra Therapeutics Inc  ALDX.O :
    * ALDEYRA THERAPEUTICS ENTERS INTO EXCLUSIVE OPTION
AGREEMENT WITH
ABBVIE FOR LICENSE TO DEVELOP AND COMMERCIALIZE REPROXALAP
    * ALDEYRA THERAPEUTICS ENTERS INTO EXCLUSIVE OPTION
AGREEMENT WITH
ABBVIE FOR LICENSE TO DEVELOP AND COMMERCIALIZE REPROXALAP
    * ALDEYRA THERAPEUTICS INC-  ABBVIE HAS OPTION TO ACQUIRE A
CO-EXCLUSIVE LICENSE TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE
REPROXALAP IN U.S.
    * ALDEYRA THERAPEUTICS -UNDER TERMS OF LICENSE AGREEMENT, CO
WOULD
BE ELIGIBLE TO RECEIVE UP TO $300 MILLION IN REGULATORY AND
COMMERCIAL MILESTONE PAYMENTS
    * ALDEYRA THERAPEUTICS INC- UNDER TERMS,  ABBVIE HAS
EXCLUSIVE
LICENSE TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE REPROXALAP
OUTSIDE U.S
    * ALDEYRA THERAPEUTICS- CO TO GET OPTION FEE OF $1 MILLION &
UPFRONT PAYMENT OF $100 MILLION LESS OPTION FEES IF ABBVIE
CHOOSES TO EXERCISE OPTIONS UNDER DEAL

Source text for Eikon:  ID:nBw7PL7P1a 
Further company coverage:  ALDX.O 

 ((Reuters.briefs@thomsonreuters.com;))